Theresa Heggie is currently CEO of Freeline, a clinical stage biotechnology company developing transformative AAV vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. She previously served as Senior Vice President, Head of Europe, Middle East and Africa (EMEA) and Canada for Alnylam Pharmaceuticals and as Global Chief Strategy and Marketing Officer for Bupa. Prior to Bupa, Ms. Heggie was Senior Vice President of Global Commercial Operations for the rare disease business at Shire, where, following the acquisition of Jerini by Shire, she was appointed CEO of Jerini AG. Ms. Heggie joined Shire in 2005 as part of the acquisition of Transkaryotic Therapies (TKT), where she was general manager for EMEA. Prior to joining Shire, Ms. Heggie held a variety of positions at Baxter Healthcare, Ohmeda Pharmaceutical Products Division and Janssen Pharmaceuticals. She serves on the boards of directors of BioCryst Pharmaceuticals and ProQR Therapeutics. Ms. Heggie received her Bachelor of Science degree from Cornell University.